Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Observational studies

Benzodiazepine use in Alzheimer’s disease linked to pneumonia risk

Study adds to evidence for link between benzodiazepines and adverse respiratory effects in people with Alzheimer’s, and suggests that risk of use should be carefully weighed against the benefits.

Close up of elderly personr taking diazepam tablet

Source: Dr P Marazzi / Science Photo Library

Data from a Finnish registry suggest patients with Alzheimer’s taking benzodiazepines are at a 28% increased risk of pneumonia compared with patients who are not prescribed the drugs.

People with Alzheimer’s disease who are taking benzodiazepines have an increased risk of developing pneumonia, a large study suggests.

Using national Finnish registry data on people with Alzheimer’s living in the community, researchers compared the effects of benzodiazepines and Z-drugs, another class of other sedative drugs, with those not prescribed either treatment.

In the analysis of 5,232 patients with Alzheimer’s taking benzodiazepines, the researchers found a 28% increased risk of pneumonia diagnosis when compared with the same number of patients with the disease who had not been prescribed the drugs.

There was no statistically increased risk of taking Z-drugs in the analysis of 3,269 patients and case-matched controls, but the study did not directly compare the drugs with benzodiazepines.

The study, published in the Canadian Medical Association Journal[1], found that the risk of pneumonia was highest during the first 30 days of taking benzodiazepines (hazard ratio 2.09). Patients in the study were more likely to be female and had an average age of 80 years.

Heidi Taipale, study leader and researcher at the School of Pharmacy, University of Eastern Finland, says that the study adds to the evidence that benzodiazepines should be used cautiously in this population, but that it takes time to change prescribing patterns. “Benzodiazepines have been the basic option for pharmacological treatment of behavioural and psychological symptoms of dementia for decades.

Heidi Taipale, the study leader and a researcher at the University of Eastern Finland School of Pharmacy

Source: Courtesy of Heidi Taipale

Heidi Taipale, study leader and researcher at the School of Pharmacy, University of Eastern Finland, says the study adds to the body of evidence that benzodiazepines should be used cautiously in patients with Alzheimer’s, but acknowledges that it takes time to change prescribing behaviours.

“Lack of effective and safe alternatives for benzodiazepines is also a problem. More focus should be put on non-pharmacological options, both research on the effectiveness of non-pharmacological treatments among persons with dementia and how they can be implemented in clinical practice,” she adds.

One theory put forward by the researchers, based at several institutions across Finland, is that the sedative effects of benzodiazepines may increase the risk of pneumonia by boosting the likelihood of aspiration of saliva or food into the lungs.

This theory correlates with the study’s finding that pneumonia risk is highest at the start of benzodiazepine use, as the sedative effect is more pronounced initially before tolerance is built up, the researchers say.

Evidence increasingly supports a link between these drugs and adverse respiratory effects, which suggests that more research is needed to fully understand the mechanisms underpinning the risk, they add.

In an accompanying editorial[2], Paula Rochon from Women’s College Hospital and the University of Toronto, Canada, said the study was a reminder of the problems associated with prescribing these drugs in frail older patients.

“Non-pharmacologic approaches should be the starting point when managing neuropsychiatric symptoms in this patient population, which should help to limit inappropriate use of these drugs,” she says.

Rosa Sancho, head of research at Alzheimer’s Research UK, says: “Benzodiazepines can be given to people with Alzheimer’s to help calm very aggressive behaviour, but their use must be carefully weighed up against the risk of side effects for each individual.

“This new study suggests that the increased risk of pneumonia should be taken into account.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202585

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £52.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £37.00Buy now
  • Minor Illness or Major Disease

    Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £42.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £32.00Buy now
  • Sampson's Textbook of Radiopharmacy

    Sampson's Textbook of Radiopharmacy

    This well-established textbook provides specialised information on the use of radiopharmaceuticals in the detection and treatment of diseases.

    £79.00Buy now
  • Zoonoses

    Zoonoses

    An accessible textbook covering zoonotic diseases, which affect humans but are contracted from animals.

    £47.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Close up of elderly personr taking diazepam tablet
  • Heidi Taipale, the study leader and a researcher at the University of Eastern Finland School of Pharmacy

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.